Dexamethaxone
Sodium Phosphate (Decadron) |
Category:
Description:
Indications:
-
Anti-inflammatory
or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic,
inflammatory, neoplastic, and autoimmune origin
Contraindications:
-
Systemic
fungal infections
-
Hypersensitivity
to any component of the product, including sulfites. Dexamethasone sodium phosphate contains sodium bisulfite, a
sulfite that may cause allergic-type reactions, including anaphylactic
symptoms and life-threatening or less severe asthmatic episodes in
certain susceptible people.
Precautions:
-
Pregnancy
category C: Newborns may exhibit signs of adrenal insufficiency;
excreted in breast milk and may suppress growth and cause other
unwanted effects
-
Psychotic
derangements may appear
-
Following
prolonged therapy, withdrawal symptoms may include fever, myalgia,
arthralgia, and malaise
-
Use
lowest possible dose
Adverse
Reactions (Side Effects):
-
METAB:
sodium retention, fluid retention, CHF, potassium loss, hypokalemic
acidosis, hypertension, negative nitrogen balance
-
MS:
muscle weakness, osteoporosis, steroid myopathy, tendon rupture,
pathological fracture of long bones, vertebral compression fractures
-
GI:
peptic ulcer, pancreatitis, abdominal distention, ulcerative
esophagitis
-
SKIN:
erythema, increased sweating, petechiae and ecchymoses, urticaria
-
ENDO:
cushionoid state, supressed growth, menstrual irregularities,
hirsutism, secondary adrenocortical and pituitary unresponsiveness
-
NEURO:
convulsions, vertigo, headache, psychic disturbances, increased
intracranial pressure with papilledema
-
OTHER:
weight gain, increased appetite, thromboemolism, hiccups, nausea,
malaise
|
Dosage:
For
intravenous, intramuscular, intraarticular, intralesional, and soft tissue
injection
Dexamethasone
sodium phosphate injection can be given directly from the vial, or it can
be added to Sodium Chloride Injection or Dextrose Injection and
adminsitered by intravenous drip.
Dosage
requirements are variable and must be individualized on the basis of the
disease and the response of the patient.
Persons
on immunosuppressant doses should avoid exposure to chickenpox or measles;
if exposed, they should seek medical advice without delay |
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|